

Multi-omics profiling reveals protective function of *Schisandra* lignans against acetaminophen-induced hepatotoxicity

**Caixia Yan^{1a}, Huimin Guo^{1a}, Qingqing Ding^{1b}, Yuhao Shao^a, Dian Kang^a,
Tengjie Yu^a, Changjian Li^a, Haoran Huang^a, Yisha Du^a, He Wang^a, Kangrui Hu^a,
Lin Xie^a, Guangji Wang^{**a}, Yan Liang^{*a}**

a. Key Lab of Drug Metabolism & Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Tongjiaxiang 24, Nanjing 210009, P.R. China

b. Department of Geriatric Oncology, First Affiliated Hospital of Nanjing Medical University (Jiangsu People's Hospital), No. 300 Guangzhou Road, Nanjing 210029, P.R. China

* Corresponding author. Tel.: +86 25 83271060; fax: +86 25 83271060;

E-mail addresses: liangyan0679@163.com; guangjiwang@hotmail.com

¹ These authors contributed equally to this work.

Running Title Page

Multi-omics analysis of Schisandra lignans liver protection

Corresponding author: Yan Liang

Co- corresponding author: Guangji Wang

Key Lab of Drug Metabolism & Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Tongjiaxiang 24, Nanjing 210009, China.

Tel: +86-25-83271060

Email: liangyan0679@163.com

guangjiwang@hotmail.com

C.Yan and H.Guo contributed equally to this work.

Number of text pages: 43

Number of figures: 7

Number of references: 53

Number of words in the Abstract: 199

Number of words in the Introduction: 702

Number of words in the Discussion: 1335

Abbreviations: ACC1, acetyl CoA carboxylase1; APAP, acetaminophen; ALF, acute liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCA, bicinchoninic acid; BP, biological process; CC, cellular component; CERs, ceramides; DAGs, diglycerides; DGAT2, diacylglycerol acyltransferase 2; DAGT2i, inhibitor of DGAT2; DTT, dithiothreitol; FABPs, Fatty acid-binding proteins; FASN, fatty acid synthetase; FATP5, fatty acid transport protein 5; FATPs, Fatty acid transport

proteins; GO, gene ontology; HBSS, Hank's balanced salt solution; IAM, iodoacetamide; IDA, information dependent acquisition; lipin1, phosphatidic acid phosphatase; IS, internal standard; L-FABP, liver type fatty acid binding protein; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LPIs, lysophosphatidylinositols; MF, molecular function; MPA, mobile phase A; MPB, mobile phase B; MSTFA, N-methyl-n-trimethylsilane trifluoroacetamide; NAFLD, Non-alcoholic fatty liver disease; NIST, National Institute of Standards and Technology; OPLS-DA, orthogonal partial least squares-discriminate analysis; PAs, phosphatidic acids; PAPs, phosphatidic acid phosphatases; PC, phosphatidylcholine; PCA, principal component analysis; PE, phosphatidylethanolamine; PIs, phosphatidylinositols; PKC, protein kinase C; PMSF, phenylmethylsulfonyl fluoride; PNL, propranolol; PS, phosphatidylserine; SLE, Schisandra lignan extract; SMs, sphingomyelins; TAGs, triglycerides; TCMs, traditional Chinese medicines; VIP, Variable importance in the projection

Abstract

The action principles of traditional Chinese medicines (TCMs) feature multi-active components, multi-target sites, and weak combination with action targets. In the present study, we performed an integrated analysis of metabonomics, proteomics and lipidomics to establish a scientific research system on the underlying mechanism of TCMs, and *Schisandra* lignan extract (SLE) was selected as a model TCM. In metabonomics, several metabolic pathways were found to mediate the liver injury induced by acetaminophen (APAP), and SLE could regulate the disorder of lipid metabolism. The proteomic study further proved that the hepatoprotective effect of SLE was closely related to the regulation of lipid metabolism. Indeed, the results of lipidomics demonstrated that SLE-dosing has an obvious callback effect on APAP-induced lipidic profile shift. The contents of 25 diglycerides (DAGs) and 21 triglycerides (TAGs) were enhanced significantly by APAP-induced liver injury, which could further induce liver injury and inflammatory response by up-regulating protein kinase C (PKC β , PKC γ , PKC δ and PKC θ). The up-regulated lipids and PKCs could be reversed to the normal level by SLE-dosing. More importantly, phosphatidic acid phosphatase (lipin1), fatty acid transport protein 5 (FATP5) and diacylglycerol acyltransferase 2 (DGAT2) were proved to be positively associated with the regulation of DAGs and TAGs.

KEY WORDS Multi-omics; *Schisandra* lignan extract; Hepatoprotective effect; Diglycerides; Triglycerides

Significance statement

Integrated multi-omics was first used to reveal the mechanism of APAP-induced acute liver failure (ALF) and hepatoprotective role of SLE. The results showed that the ALF caused by APAP was closely related to lipid regulation and SLE-dosing could exert hepatoprotective role by reducing intrahepatic DAG and TAG levels. Our research can not only promote the application of multi-component technology in the study of the mechanism of TCMs, but also provide an effective approach for the prevention and treatment of ALF.

1.Introduction

TCMs are essential parts of the health care system for diagnosis, prevention and treatment of diseases in several Asian countries, and are considered as a complementary or alternative medical system in many western countries(Yan et al., 2018). However, the modernization and internationalization of TCM are always hampered by its chemical complexity, unknown targets, and combinatorial use tradition guided by esoteric principles(Zhang et al., 2019a). Recent years saw many studies utilize “omics” technology to elucidate the biological foundation of TCMs. For instance, proteomics has been revolutionized by MS-based methods, and frequently utilized to measure the therapeutic effect of TCM treatments(Ohyama et al., 2015; Selevsek et al., 2015; Lin et al., 2012; Lan et al., 2018; Liu et al., 2018; Zhang et al., 2018b). Metabonomics, another omics approach, can also provide powerful technique for the identification of noninvasive biomarkers and improve the diagnosis of complex diseases(Emwas et al., 2015). So far, metabonomics has gained enormous attention in the TCM research because the elucidation of the metabolic pattern for different syndromes is the root for understanding the actions of TCMs(Li et al., 2013). In addition, fatty acids are important signal molecules that regulate many cellular processes, from inflammation to neural function. Altered lipid profiles associated with disease progression will provide new insights into the pathogenic mechanisms of chemical-induced activity toxicity in disease(Yang et al., 2016; Titz et al., 2018; Xu et al., 2019b). In a word, “omics” technologies provide an opportunity to understand the flow of information that underlies TCMs.

APAP overdose is the most common cause of acute liver failure (ALF) and even death in the western world(Bernal et al., 2015). Despite mechanisms of drug-induced liver injury have been extensively investigated to develop novel therapeutic strategies, current treatment options after APAP-overdose are extremely limited(Bhushan and Apte, 2019).The main reason is that most of the patients seek medical attention late, the injury is already formed and difficult to reverse. To date, N-acetylcysteine (NAC) is still the only clinically recognized pharmacological intervention in patients with APAP overdose. However, NAC intervention is only effective within 24 hours after APAP overdose. Long-term use of NAC is even harmful to recovery after APAP overdose(Athuraliya and Jones, 2009). Rational, effective approaches for the prevention and treatment of APAP-induced ALF are, therefore, urgently required. *Schisandra chinensis* (Turcz.) Baill, a Magnoliaceae family plant abundant in orient, is regarded as a medical herb in both TCM and western herbal medicine(Panossian and Wikman, 2008). Many studies have shown that *Schisandra* lignans has various pharmacological effects, such as liver protection, antioxidation, anti-lipid peroxidation, anti-cancer and anti-HIV effect and so on(Kuo et al., 2001; Panossian and Wikman, 2008; Li et al., 2014; Jiang et al., 2015; Zhang et al., 2019b). In our previous study, a series of solvents (10 %, 50 % and 90 % of ethanol) was used to extract lignans, and the corresponding SLEs were defined as 10 % SLE, 50 % SLE, and 90 % SLE. The hepatoprotective effect of SLEs on APAP induced liver injury were compared via histopathological analysis and determining the levels of ALT, AST, GSH and SOD in mice and primary hepatocytes, and N-acetylcysteine (NAC) was used as a positive drug. The results demonstrated that SLEs pretreatment could remarkably ameliorate APAP-induced ALF by reducing ALT, AST and oxidative stress levels. The hepatoprotective activity of 50 % SLE was significantly higher than

that of 10 % SLE and 90 % SLE(Kang et al., 2019).

To date, the research on hepatoprotective effect of *Schisandra* lignans was mainly focused on their apparent efficacy. To our knowledge, the integrated application of multi-omics to characterize the APAP-induced hepatotoxicity and hepatoprotective effect of SLE has not yet been reported. The present study aimed to develop a practical strategy for identifying the targets and mechanism of multi-component action of TCMs and provide an effective approach for the prevention and treatment of ALF induced by APAP overdose. Based on the systematic biological approaches of metabolomics and proteomics, it was proved that the APAP-induced hepatotoxicity and the hepatoprotective effect of SLE were positively correlated with the regulation of lipid metabolism. Then the lipidomics approach was used to identify the lipids that mediate the SLE's hepatoprotective effect. APAP-induced hepatic toxicity was proved to enhance the levels of intrahepatic DAGs and TAGs, which could be reversed to the normal level by SLE-dosing.

2. Materials and methods

2.1 Materials

Schisandra sphenanthera was purchased from Anhui Songshan Tang Chinese medicine Ltd. (Bozhou, Anhui, China). APAP was purchased from Maclin Biochemical Co. Ltd. (Shanghai, China). Collagenase I, percoll, 1,2-¹³C₂-mycolic acid, methoxyamine hydrochloride, N-methyl-n-trimethylsilane trifluoroacetamide (MSTFA), phenylmethylsulfonyl fluoride (PMSF), dithiothreitol (DTT), iodoacetamide (IAM), hexadecane diacylglycerol (C16:0), PF-06424439, lysophosphatidylcholine (LPC, 17:0), lysophosphatidylethanolamine (LPE, 14:0), phosphatidylcholine (PC, 14:0/14:0), phosphatidylethanolamine (PE, 14:0/14:0),

triradylglycerol (TAG, 17:0/17:0/17:0), and phosphatidylserine (PS, 14:0/14:0), were purchased from Sigma-Aldrich Chemicals (St. Louis, MO, USA). 5-¹³C-glutamine was purchased from Cambridge Isotope Laboratories, Inc. (Tewksbury, MA, USA). The assay kits for the measurement of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were purchased from Nanjing Jiancheng Institute of Bioengineering (Nanjing, Jiangsu, China). HPLC-grade acetonitrile and methanol were purchased from Merck (Merck Company, Darmstadt, Germany). Ultra-pure grade water was prepared by the Milli-Q system (Millipore Corporation, Billerica, MA, USA).

2.2 *Animals and Treatments*

2.2.1 *Animals*

Male C57BL/6J mice (6 weeks, weighing 18~20 g) were purchased from Vital River Laboratory Animal Technology CO., Ltd. (Beijing, China), and housed under controlled condition (25 °C, 55–60 % humidity and 12 h light/dark cycle) with free access to laboratory food and water. Animal welfare and all studies were strictly in compliance with animal care laws and guidelines, and approved by the Animal Care and Use Committee of China Pharmaceutical University.

2.2.2 *Preparation of SLE and APAP-induced liver injury model mice*

To prepare the SLE, *Schisandra sphenanthera* was powdered followed by filtration through a fine sieve (270 μm). The filtered powder was heated to reflux twice for 2 h with 50 % ethanol (w/w 1:10), and the supernatants were concentrated with rotary evaporator. *Schisandra* lignans were further extracted by 5 times volume

of ethyl acetate. The contents of Schisandrol A, Schisandrol B, Schisantherin A, Schisandrin A and Schisandrin B were determined to control the quality of SLE, and the results are shown in **Table S1**. After drying the solvent, SLE powder was dissolved with 20 % PEG-400 solution to form SLE emulsion. To prepare APAP-induced liver injury model mice, APAP was dissolved in saline (0.9 % NaCl), slightly heated and injected intraperitoneally at a dosage of 400 mg/kg to mice. Then the mice regained free access to water. A total of 21 mice were divided into 3 groups (n=7). In the control group, the mice were only treated with blank solvent. In the APAP group, the mice were intraperitoneally administrated with APAP at a dose of 400 mg/kg. In the SLE+APAP group, SLE was administered intragastrically at a dosage of 500 mg/kg for 3 consecutive days (twice a day). In the propranolol (PNL) group and the PNL+APAP group, the mice were intraperitoneally administrated with PNL once at a dose of 80 mg/kg. Then the mice were intraperitoneally administrated 400 mg/kg of APAP at 1h after the last administration of SLE or PNL. All mice were sacrificed under anesthesia at 4 h after intraperitoneally injection of APAP, and blood samples and liver tissues were collected on ice plate.

2.3 Culture of primary mouse hepatocytes

Primary mouse hepatocytes were cultured in accordance with our previously developed methods (Kang et al., 2019). The ethylene glycol tetraacetic acid solution (0.5 mM) was prepared in HEPES-buffered Hank's balanced salt solution (HBSS; pH 7.4). The liver of mice was perfused with ethylene glycol tetraacetic acid solution for

5 min at 40 °C. The portal vein of the liver was cut off rapidly, and the blood and calcium ions were removed. Then the liver was perfused with HEPES-buffered HBSS. Hepatocytes were dispersed, washed, and purified on Percoll density gradient. The isolated hepatocytes were seeded in rat tail collagen-coated 24-well cell culture plate at a density of 2.5×10^5 cells / mL.

2.4 Metabonomics analysis of mouse liver using GC-MS

The samples of mouse liver and GC-MS analysis were processed as reported previously (Cao et al., 2013). Briefly, $^{13}\text{C}_2$ -myristic acid (12.5 µg/mL) was used as internal standard (IS). A ULTRA-TURRAX T25 homogenizer was used to homogenize 20 mg of liver tissue, and 30 µL of methoxyamine hydrochloride in pyridine (10 mg/mL) was added to the residue. After derivatizing for 16 h, 30 µL of the N-methyl-n-trimethylsilane trifluoroacetamide (MSTFA) reagent (1 % TMCS, v/v) was added. Finally, 30 µL of heptane solution containing external standard methyl myristate (30 µg / mL) was used as dissolving solvent. GC-MS analysis was performed using a Shimadzu GC-MS QP2010 Ultra gaschromatograph system coupled with mass spectrometer (Shimadzu Corporation, Kyoto, Japan). The MS data were acquired in full-scan mode with the m/z range of 50–700 at an acquisition rate of 5000Hz. GC-MS solution software (Shimadzu Corporation, Kyoto, Japan) was used for the raw data acquisition and processing. Principal component analysis (PCA) and orthogonal partial least squares-discriminate analysis (OPLS-DA) were performed using SIMCA version 14.0.1 (Umetrics, Sweden) and MetaboAnalyst 4.0 (<http://www.metaboanalyst.ca/>). Statistical analyses were conducted by SPSS

software version 19.0 (IBM Corp., Armonk, USA). Heat maps and hierarchical cluster analyses were conducted using MeV 4.6.0 software.

2.5 Proteomics analysis of mouse liver using LTQ-Orbitrap XL MS

The samples of mouse liver and LTQ-Orbitrap XL MS analysis were processed as we described previously (Shao et al., 2017). Briefly, mouse liver (200 mg) was grinded in liquid nitrogen, and 2 mL of RIPA lysate (containing 10 mM PMSF) was added to extract proteins. Then 200 µg of proteins were added in 10 kDa ultrafiltration tube, then denaturation, alkylation and trypsin digestion were carried out. The digestion reaction was terminated by 1 µL of trifluoroacetic acid. After centrifuging at 14000 g for 10 min, the effluent was collected and dried in a vacuum concentrator. The evaporated sample was re-dissolved with 50 µL of 0.1 % formic acid aqueous solution and then desalted using zip-tip C18 tips. On-line separation and determination of digested liver specimen were performed using an Ultimate 3000 RSLC nano system coupled to a LTQ-Orbitrap XL MS (Thermo Fisher Scientific, San Jose, CA). A sample equivalent to 10 µg protein was injected onto the reversed-phase trap column (Acclaim PepMap100 C18, 75 µm × 2 cm, 3 µm, 100 Å, Thermo Scientific). A series of nano-flow gradients was used to back-flush the trapped samples onto the nano-LC column (Acclaim PepMap® RSLC, C18, 75 µm × 15 cm, 3 µm, 100Å, Thermo Scientific, San Jose, CA) for chromatographic separation. The LTQ-Orbitrap XL MS was operated in a data-dependent mode to switch between MS¹ and MS/MS automatically. MS¹ survey scans (m/z 350-1800) were performed with a resolution of 60,000 at m/z 400. Electrospray voltage was 2.2 kV. Raw data were

processed using Proteome Discoverer version 1.4 (Thermo Fisher Scientific, Waltham, MA, USA). Protein identification was performed using Sequest HT engine combining *Rattus norvegicus* database (Taxonomy 9606, <http://www.uniprot.org/proteomes/>).

2.6 Lipidomics analysis of mouse liver using LC-Q-TOF MS

Mouse liver (50 mg) was homogenized in 200 μ L of 75 % methanol and 10 μ L of the mixed internal standard solution (containing 40 μ g/mL LPC 17:0, 200 μ g/mL PC 14:0/14:0, 200 μ g/mL LPE 14:0, 200 μ g/mL PE 14:0/14:0, 400 μ g/mL PS 14:0/14:0, 100 μ g/mL TAG 17:0/17:0/17:0) , followed by adding 500 μ L of methyl tert-butyl ether. After vortex mixing for 1 h, 125 μ L of H₂O was added and settled for 5 min. The supernatant was dried and then re-dissolved in acetonitrile-isopropanol-water (60:35:5, v/v/v).

LC separation was performed using a Shimadzu UFLC-30A system (Shimadzu, Kyoto, Japan). All the components were eluted onto a Shimadzu Shim-pack VP-ODS column (5 μ m, 150 \times 2.0mm I.D, Shimadzu). MPA was acetonitrile-water (60:40, v/v) containing 10 mmol/L of ammonium formate. MPB was acetonitrile: isopropanol (10:90, v/v) containing 10 mmol/L ammonium formate. A 30-min gradient elution was as follows: 0 - 7 min, 30 % MPB; 7 - 25 min, 30–100 % MPB; 25 - 30 min, 30 % MPB. MS analysis was performed using an AB Sciex 5600+ Triple TOF MS system (Concord, Ontario, Canada), which operated in positive and negative ionization mode, respectively. The MS parameters were set as follows: gas 1 50 psi, gas 2 50 psi, curtain gas 35 psi, MS¹ scan range 400 - 1000 (*m/z*), MS² scan range 100 - 1000 (*m/z*). In positive ionization mode, ion-spray voltage floating was 5.5 kV, and collision

energy was 35 V. In negative ionization mode, ion-spray voltage floating was -4.5 kV, and collision energy was -35 V. All the parameters LC and MS were controlled by Analyst TF 1.7 software (Sciex, Concord, Ontario, Canada). Peak recognition, extraction and alignment were performed on MasterView 2.0 software (Sciex, Concord, Ontario, Canada). MS² fragment ions of lipids were identified and confirmed by PeakView 1.2 software (Sciex, Concord, Ontario, Canada) combining LipidBlast database. All the peaks were integrated by Multiquant 2.0 (Sciex, Concord, Ontario, Canada).

2.7 Bioinformatics analysis of protein data

The gene ontology (GO) function annotation of differential proteins was analyzed from 3 aspects of biological process (BP), molecular function (MF) and cellular component (CC) by Blast GO to further understand the function of the 72 common differential proteins in the process of SLE's liver protection. Then the KEGG database was used to analyze the main biochemical metabolic pathways and signal transduction pathways involved in differential expression protein.

2.8 Determination of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities in serum

Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities were measured using commercial kits (Nanjing Jiancheng Institute of Biotechnology, Nanjing, China) by Reitman-Frankel colorimetric end point method. Absorbance was determined using a Synergy H1 microplate reader of multi-wavelength measurement system (BioTek Instruments, Inc, Winooski, VT,

USA) at 510 nm.

2.9 Quantitative reverse transcription polymerase chain reaction analysis

Total RNA was extracted from the liver samples using Trizol (Invitrogen Co., San Diego, CA, USA). The RNA concentration and quality were determined using a Synergy H1 microplate reader of multi-wavelength measurement system (BioTek Instruments, Inc, Winooski, VT, USA). cDNA was synthesized using a High-Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA, USA). Quantitative RT-PCR was performed using the Thermal Cycler Dice™ Real Time System (TaKaRa Code: TP800). The primer sets for the target genes were list in **Table S2**. Amplifications were performed starting with a 1 min at 95 °C for template denaturation, followed by 40 cycles at 95 °C for 15 s and 72 °C for 0.5 min. The PCR amplifications were performed in a T3 Thermocycler (Biometra). The relative amounts of the RNAs were calculated using the comparative C_T method.

2.10 Western Blotting Analysis of lipin1 and lipin2

For Western blots, mouse liver was prepared as we previously described (Chen et al., 2020). Briefly, mouse liver was homogenized and diluted using 4x premixed protein sample buffer. The wells of a 6 % acrylamide-bisacrylamide gel were loaded with 80 µg of protein. After being separated on a 10 % SDS-polyacrylamide gel, the proteins were transferred onto a polyvinylidene difluoride membrane. Then the proteins were subsequently transferred to a membrane (FFP24; Beyotime, China), blocked in 5 % nonfat milk. After being washed for 30 minutes, the membrane was incubated in appropriate secondary antibodies. Bound immunoglobulins were

visualized with the BeyoECL Star (Beyotime, China) on BIO-RAD ChemiDoc XRS⁺. Grayscale analysis was carried out using Image J software (National Institutes of Health-Open Source).

2.11 Statistical Analysis

Student t test or ANOVA were used to compare 2 groups and 3 or more groups, respectively. GraphPad Prism software (version 7.0) was used to calculate statistical significance. Statistically significant difference was considered for $P < 0.05$.

3. Results

3.1 Metabolomic investigation of APAP-induced hepatotoxicity and hepatoprotective function of SLE

The hepatoprotective effect of SLE on APAP induced liver injury were compared via analyzing the pathological sections and determining the levels of ALT and AST in mouse liver samples of control, SLE, APAP and SLE+APAP groups. As shown in the **Fig. S1**, SLE has no significant effect on the liver of healthy mice, but can significantly alleviate the liver toxicity of APAP-induced liver injury mice.

The stability and repeatability of the GC-MS system for metabolomics analysis were validated by examining the retention time of the IS and the repeatability of pooled QC samples. After GC-MS analysis of mouse liver samples of control, APAP and SLE+APAP groups, a total of 64 compounds, including organic acids, sugars, purines, and amino acids, were identified by comparing the mass spectrum information of metabolites in National Institute of Standards and Technology (NIST) and Wiley libraries. After normalizing the peak area of the identified metabolites with the IS, the pattern recognition technique, supervised OPLS-DA, was used to partition

the data of control, APAP and SLE+APAP groups. Sample distribution pattern in the score scatter plot indicated that there were significant differences in the metabolic profiling of mouse liver among the three groups (**Fig. 1A**). Compared with the control group, the metabolic profiling of the APAP group was shifted to the upper right direction, and SLE-dosing made the metabolic profiling move to the left quadrant, which suggested that SLE-dosing had an obvious callback effect on APAP induced liver metabolic profiling shift. The GC-MS spectra of the metabolites were analyzed based on mass spectra libraries, and the differential metabolites had to meet the criteria Variable importance in the projection (VIP)>1 and $P < 0.05$. A total of 35 kinds of differential small metabolites, mainly including maltose, adenylate, alanine, glucose-6-phosphate, were screened from the liver samples. Besides, heat maps were created based on the average change fold of differential metabolites to intuitively evaluate their variation tendency among the control, APAP and SLE+APAP groups. Obviously, the levels of glycine, maltose, adenylate, phenylalanine, glucose-6-phosphate, xylose, lactate, threonine, alanine, and proline in the liver of model mice were significantly lower than those of conventional mice. Administration of SLE could up-regulate the intrahepatic concentrations of these metabolites (**Fig. 1B**). MetaboAnalyst software was used to enrich the pathway of these differential metabolites based on KEGG (Kyoto Encyclopedia of genes and genomes) database, allowing us to identify enriched pathways from the differential expression profiling data and visualize changes in metabolite data by analyzing networks of genes and compounds. The results were shown in **Fig. 1C** and **Table S3**, urea cycle, ammonia recycling, arginine and proline metabolism, purine metabolism, glutamate metabolism, alanine metabolism, malate-aspartate shuttle, aspartate metabolism, gluconeogenesis, glucose-alanine cycle, nicotinate and nicotinamide metabolism, phenylalanine and

tyrosine metabolism, glutathione metabolism, seleno amino acid metabolism, galactose metabolism, glycine and serine metabolism, phenylacetate metabolism, lactose degradation, glycolysis, cysteine metabolism, starch and sucrose metabolism were found to play important roles in APAP induced hepatotoxicity and hepatoprotective effect of SLE. The changes of urea cycle, ammonia recycling, arginine and proline metabolism were the most significant among the control, APAP and SLE+APAP groups. The disorder of urea cycle and ammonia synthesis recovery pathway can lead to the metabolism disorder of amino acids such as arginine, proline and glutamine, and then lead to the disorder of lipid metabolism. Therefore, APAP induced hepatotoxicity and hepatoprotective effect of SLE may be closely related to lipid metabolism of liver.

3.2 Proteomic investigation of APAP-induced hepatotoxicity and hepatoprotective function of SLE

The whole protein of liver tissues of mice in control, APAP and SLE+APAP groups was analyzed by LTQ-Orbitrap XL MS after a series of pretreatment processes such as denaturation, reduction, alkylation, enzymolysis and desalting. A total of 7477 peptides and 1405 proteins were identified in mouse liver. All the identified proteins were quantitatively analyzed using MaxQuant (version 1.5.3) software based on Label-Free method. PCA analysis was performed on the proteomic data of control, APAP and SLE+APAP groups, and the results were shown in **Fig. 2A**. There was a significant difference in the proteome between the control group and APAP-induced liver injury groups. The regulation multiple >1.2 or <0.8 and P value <0.05 were used as the screening criteria to screen differential protein. A total of 133 differential

proteins were identified between control and APAP groups, accounting for 9.4 % of the total protein number. After APAP modeling, 78 differential proteins were significantly up-regulated and 55 differential proteins were significantly down-regulated (**Fig. 2B**). We also screened the differential proteins in the livers of the APAP and the SLE+APAP groups. Compared with the APAP group, 162 differential proteins were found in the SLE+APAP group, accounting for 11.5 % of the total protein number. After SLE treatment, 81 differential proteins were significantly up-regulated and 81 differential proteins were significantly down regulated (**Fig. 2C**). The overlapping relationship between the differential proteins of the control group and the APAP group and the differential proteins of the APAP group and the SLE+APAP group was shown in Venn Diagram, with a total of 72 protein overlaps (**Fig. 2D**). These results suggested that SLE might exert hepatoprotective effect by regulating these 72 differential proteins.

As shown in **Fig. 3A**, the differential proteins involved in 1757 biological processes, 547 of which had significant difference ($P < 0.05$). In addition, the differential proteins had 279 molecular functions, 116 of which had significant difference ($P < 0.05$). The differentially expressed proteins were enriched into 57 signal pathways in KEGG database, 13 of which had significant difference. Next, we enriched the BP function of the differential proteins. The results suggested that the main biological functions of the differential proteins included cell attachment and location, cell composition or synthesis, cell development process, biological regulation, immune process, metabolic process, response to stimulation, *etc.*(**Fig.**

3B). We mapped the protein-protein interaction of the differentially expressed proteins in the metabolic pathways. As shown in **Fig. 3C**, APAP-induced hepatotoxicity could significantly down regulate mug1, spa1b, serpin6b, pdia6 and CFL1, while SLE-dosing could significantly reverse the down-regulation of these proteolysis related proteins. APAP-induced hepatotoxicity could also significantly down-regulate glutathione transferases (Gstt3, Gstm1, Gstm2, Gstm3 and Gsta4) and platelet aggregation related proteins (Fga, Fgb and Fgg), while SLE-dosing could significantly reverse the down-regulation of these proteins. It should be noticed that, SLE could exert hepatoprotective effect on APAP induced hepatotoxicity by regulating the related proteins of lipid metabolism, including Cyp4a10, Cyp2b10, Akr1d1, Hadh, Aldh, Por, CES1G, Amacr, FABP1.

3.3 Lipidomic investigation of APAP-induced hepatotoxicity and hepatoprotective function of SLE

The above results of metabonomics and proteomics both showed that the hepatoprotective effect of SLE was related to the lipid metabolism in mouse liver. Herein, lipidomics of mouse liver in control, APAP and SLE+APAP groups were compared to identify the lipids related to the hepatoprotective effect of SLE. SCIEX 5600 Q-TOF MS was used to detect the lipids in mouse liver, and information-dependent acquisition (IDA) was used under ESI positive and negative mode respectively. A total of 211 kinds of lipids, including 57 triglycerides (TAGs), 43 phosphatidylcholine (PCs), 22 phosphatidylethanolamines (PEs), 22 kinds of diglycerides (DAGs), 16 phosphatidylinositols (PIs), 12 sphingomyelins (SMs), 12

phosphatidylserines (PSs), 8 lysophosphatidylcholines (LPCs), 7 lysophosphatidylethanolamines (LPEs), 6 ceramides (CERs), and 3 lysophosphatidylinositols (LPIs), were identified in mouse liver (**Fig. 4A**). In addition, there were significant differences in the lipid profiling of mouse liver among the control, APAP and SLE+APAP groups (**Fig. 4B**).

A total of 22 DAGs were identified in mouse liver, and DAG (16:0/18:2/0:0), DAG (18:1/18:1/0:0) and DAG (16:0/18:1/0:0) were much higher in content than other DAGs. In APAP-induced liver injury model mice, the content of 21 DAGs was significantly higher than that in normal mice, and SLE-dosing could significantly reduce the content of these DAGs (**Fig. 4C**). The change folds of DAGs in control, APAP and SLE+APAP groups were shown in **Table S4**. A total of 57 TAGs were identified in mouse liver. In APAP-induced liver injury model mice, the content of 25 TAGs was significantly higher than that in control mice, and SLE-dosing could significantly reduce the levels of 6 kinds of TAGs (**Fig. 4D**). The change folds of TAGs in control, APAP and SLE+APAP groups were shown in **Table S5**. In addition, the liver damage caused by APAP and SLE-dosing was found to dramatically affect the levels of other lipids, such as LPC 16:0, LPC 18:0, LPC 18:1, LPC 18:2, LPC 20:0, LPC 20:1, LPC 20:4, LPC 22:6, PC(14:0/18:2), PC(14:0/16:1), PC(16:0/16:1), PE(16:1/18:3), *etc.*

3.4 Mechanism of APAP-induced hepatotoxicity and SLE on the regulation of DAGs and TAGs

Lipins are phosphatidate phosphatase enzymes that catalyze the conversion of

phosphatidic acids (PAs) to DAGs, and thus act at a branch-point for the synthesis of TAGs, zwitterionic phospholipids, or anionic phospholipids (Reue and Brindley, 2008). Herein, we measured the expressions of lipin1 and lipin2 in control, APAP and SLE+APAP groups. In the APAP-induced liver injury model group, the expression of lipin1 was significantly up-regulated, while SLE-dosing could greatly reverse the up-regulation of lipin1 (**Fig. 5A to 5C**). In addition, SLE could also reverse the expression of lipin2 mRNA to normal level, but neither APAP nor SLE had significant effect on the expression of lipin2 protein (**Fig. 5D to 5F**). CD36 is a single chain transmembrane glycoprotein on the cell surface, which is involved in the metabolism and uptake of fatty acids. In the APAP-induced liver injury mice, the expression of CD36 was significantly lower than that in control group, and SLE-dosing could not reverse the down-regulation of CD36 expression reduced by APAP (**Fig. 5G**). Fatty acid-binding proteins (FABPs) are the single most abundant proteins in the cytosol of cells, which play important roles in the utilization of fatty acids in cells. Herein, expression of the liver type fatty acid binding protein (L-FABP) in mouse liver was measured. The results suggested that the expression of L-FABP in the APAP-induced model group was significantly lower than that in control group, and SLE-dosing could not reverse the down-regulation of L-FABP expression reduced by APAP (**Fig. 5H**). Fatty acid transport proteins (FATPs) are multifunctional carrier proteins, which are involved in the synthesis of TAGs and promote the deposition of fat in the related tissues through the role of lipidization (Hatch et al., 2002). Therefore, FATPs are considered to be the most

important factor involved in fatty acid transport and fat deposition. The effect of liver injury and SLE on the expression of FATP5, a FATP subtype distributed in the liver, was investigated in the present study. As shown in **Fig. 5I**, hepatotoxicity induced by APAP could lead to up-regulation of FATP5 by about 50 times. After SLE administration, the level of FATP5 was significantly down-regulated. Some of the fatty acids used in the synthesis of DAGs were derived from de novo synthesis, and the enzymes for the de novo synthesis of these fatty acids were acetyl CoA carboxylase1 (ACC1) and fatty acid synthetase (FASN), respectively. Hepatotoxicity induced by APAP significantly reduced the expression of ACC1, while SLE-dosing had no significant effect on the expression of ACC1 (**Fig. 5J**). SLE-dosing could decrease the expression of FASN in mice with liver injury although the effect of hepatotoxicity on the expression of FASN was not significant (**Fig. 5K**). In addition, diacylglycerol acyltransferase 2 (DGAT2) is a very important enzyme, which can form TAGs by covalent bond of DAGs and acyl-CoA(Klaitong et al., 2017). Clearly, hepatotoxicity induced by APAP significantly enhanced the expression of DGAT2, and SLE-dosing could reverse the up-regulation of DGAT2 (**Fig. 5L**). Thus, the effect of APAP-induced hepatotoxicity and SLE-dosing on the regulation of DAGs and TAGs was also closely related to lipin1, FATP5 and DGAT2.

3.5 Effect and mechanism of DAGs on liver injury

Previous studies revealed that lipins activity could be inhibited by PNL(Grkovich et al., 2006; Albert et al., 2008; Brohee et al., 2015; Klaitong et al., 2017). Herein, we investigated the effect of PNL on DAGs and lipins in mice liver. PNL was found to

significantly reduce the content of DAGs in the liver of mice with APAP induced hepatotoxicity, but had no significant effect on the DAGs in the liver of control mice (**Fig.6A** and **6B**). PNL could also significantly reduce the levels of serum ALT and AST in the mice with liver injury (**Fig.6C** and **6D**). DAG (16:0/18:2/0:0) had higher level than other DAGs in mouse liver, and was used to investigate the influence of DAG on liver injury. As shown in **Fig. 6E**, DAG (16:0/18:2/0:0) could dose-dependently reduce the survival rate of mouse primary hepatocytes. In addition, the inhibitor of DGAT2 (DAGT2i, PF-06424439) was used to further investigate the influence of DAG on liver injury. The results demonstrated that 20 μ M of DAGT2i could dramatically decrease the survival rate of mouse primary hepatocytes (**Fig. 6F**), while PNL could dose dependently enhance the survival rate of hepatocytes (**Fig. 6G**).

DAGs are ligands of protein kinase C (PKC). The accumulation of DAGs in cells can activate PKC and then induce inflammation. Therefore, the levels of PKC α , PKC β , PKC γ , PKC δ and PKC θ in control, APAP and SLE+APAP groups were measured to clarify the mechanism of DAGs aggravating liver injury. There was no significant difference in PKC α expression among the three groups(**Fig. 7A**).The expression of PKC β , PKC γ , PKC δ and PKC θ in APAP-induced liver injury mice was significantly higher than that in the control group. After SLE administration, expressions of PKC β , PKC γ , PKC δ and PKC θ decreased to the normal level(**Fig. 7B to 7E**). Among these PKCs, PKC γ was most affected by liver injury and SLE-dosing. APAP-induced liver injury could up-regulate PKC γ expression 15 times, and

SLE-dosing could make PKC γ expression return to the normal level.

4. Discussion

Schisandra chinensis fructus, from the fruit of *Schisandra chinensis* (Turcz.) Baill, has been widely used in TCM for the treatment of liver diseases in clinical settings for centuries (Cheng et al., 2013; Li et al., 2018). A large number of studies have proved that lignans are the main components of *Schisandra chinensis fructus* (Liu et al., 2012; Chun et al., 2014; Zhang et al., 2018a). Just last year we also demonstrated that SLE has a definite protective effect on APAP induced liver injury on *in vivo* and *in vitro* models (Kang et al., 2019). To date approximately 150 lignans have been identified from *Schisandra chinensis fructus*. The chemical complexity, unknown targets and unclear mechanism of SLE severely hamper its modernization and internationalization.

Although previous studies have yielded multifaceted mechanistic information about hepatoprotective effect of SLE, the correlation among the metabolic events, progression of APAP-induced hepatotoxicity and hepatoprotective effect of SLE has not been extensively examined. In this study, metabonomics approach was used to characterize the mechanism and target of SLE's liver protection. Sample distribution pattern in the score scatter plot indicated that APAP-induced hepatotoxicity caused significant shift of small molecule metabolic profiling, and SLE-dosing had an obvious callback effect on APAP-induced liver metabolic profiling, which showed a novel correlation with the hepatoprotective effect of SLE on APAP-induced

hepatotoxicity(Li et al., 2018; Kang et al., 2019). It should be noticed that, compared with the control and SLE+APAP groups, urea cycle, ammonia recycling, arginine and proline metabolism were altered in response to APAP induced hepatotoxicity. Increasing evidences reveal that the disorder of urea cycle and ammonia synthesis recovery pathway can lead to the metabolism disorder of amino acids such as arginine, proline and glutamine, and then result in the metabolism disorder of lipids(Shimizu et al., 2015; Liu et al., 2019; Suzuki et al., 2019).Analyzed comprehensively, these results indicate that the APAP induced hepatotoxicity and hepatoprotective effect of SLE might be attributable in part to the metabolism of lipids in liver. To further characterize the hepatoprotective effect of SLE, proteomics, another omics approach, was used to screen the target proteins in mouse liver from a holistic perspective. In recent years, comparative proteomics has become a robust approach for the demonstration of overall protein levels, and great progress has been made in the application of proteomics to determine the mechanism of the TCMs(Liu et al., 2016; Wen et al., 2018). In the present study, proteomics approach reveals that proteolysis, platelet activation, drug metabolism, glutathione metabolism, lipid metabolic process and sulfur compound metabolic process play important roles in APAP induced hepatotoxicity and hepatoprotective effect of SLE. It is noteworthy that SLE could exert hepatoprotective effect by regulating the lipid metabolism related proteins, including Cyp4a10, Cyp2b10, Akr1d1, Hadh, Aldh, Por, CES1G, Amacr, FABP1.

Metabonomics and proteomics approaches both show that APAP-induced hepatotoxicity and hepatoprotective effect of SLE are associated with the regulation

of lipid metabolism. Further evaluation of altered liver lipids in control, APAP and SLE+APAP mouse is greatly needed to identify the lipids related to the hepatoprotective effect of SLE. The developments in lipidomics, including the combination of advanced analytical instrumentation and chemometric computation, provides another alternative technical platform for examining the lipid metabolic flux in a complex biomatrix (Shi et al., 2012; Hyotylainen and Oresic, 2016). The indiscriminant and untargeted nature of lipidomic analysis can lead to the identification of novel biomarkers that guide subsequent investigations on the mechanism of diseases and chemical-induced activities (Chen et al., 2008; Sreekumar et al., 2009). In this study, features of lipid alteration in mice liver after treatment with APAP and SLE were identified, i.e., hepatic DAGs and TAGs levels significantly increased in APAP-induced liver injury mouse, while these up-regulated lipids could be reduced to normal level by SLE-dosing. In fact, the observation of DAGs and TAGs accumulation in this study is consistent with the reported blocked glucose metabolism as the inhibition of β -oxidation of fatty acids caused by APAP (Chen et al., 2009). Generally, the main sources of hepatic DAGs and TAGs include conversion from phosphatidic acids, uptake and transport of free fatty acids, and de novo synthesis in liver.

In the process of transforming phosphatidic acids into DAGs, phosphatidic acid phosphatases (PAPs) catalyze the formation of DAGs from phosphatidic acids (PA), which are the key enzymes to regulate the levels of PA and DAG in vivo (Eastmond et al., 2010). Lipins, as lipid PAPs on endoplasmic reticulum, catalyze the

dephosphorylation of phospholipid acid to form DAGs, and lipin activity acts at a branch-point for the synthesis of triacylglycerol, zwitterionic phospholipids, or anionic phospholipids(Reue and Brindley, 2008). Previous studies suggest that lipin deficiencies are associated with the loss of normal glycerolipid synthetic capabilities as well as aberrant regulation of PA-mediated signaling cascades(Zhang and Reue, 2017). All three mammalian lipin proteins (lipin1, 2, and 3) have PAP enzyme activity, with specific activity for lipin1 somewhat higher than that for lipin2 and lipin3(Donkor et al., 2007). In this study, APAP-induced hepatotoxicity was found to significantly up-regulate lipin1, whereas the up-regulated lipin1 could be reduced to normal level by SLE-dosing. Thus, lipin1 may be one of the targets of APAP-induced hepatotoxicity and hepatoprotective effect of SLE. Uptake and intracellular trafficking of lipids are dependent on translocase (CD36), FABPs, and FATPs(Diaz et al., 2015). CD36 is a single chain transmembrane glycoprotein on the cell surface, which is involved in the uptake of long-chain fatty acids and contributes under excessive fat supply to lipid accumulation and metabolic dysfunction(Glatz and Luiken, 2017). In this study, altered CD36 expressions in control, APAP and SLE+APAP mice liver were evaluated, and the results suggest that APAP-induced hepatotoxicity significantly down-regulate CD36 expression, and SLE-dosing has no significant effect on CD36 expression. FABPs are a family of small and abundant proteins which active in long chain fatty acid uptake, transport, metabolism, oxidation, and storage(Xu et al., 2019a). Among these FABPs, liver FABP (L-FABP) is highly expressed in both hepatocytes and enterocytes, and plays a key role in high-fat

diet-induced hepatic steatosis and diet-induced NASH *in vivo* (Lin et al., 2018). Our results suggested that APAP induced hepatotoxicity can significantly down-regulate L-FABP expression, while hepatoprotective effect of SLE does not depend on the regulation of L-FABP. FATPs are multifunctional carrier proteins, which can preferentially use the fatty acids transported to the cells for the synthesis of TAGs and promote the deposition of fat in the related tissues through the role of lipidization (Hatch et al., 2002). In general, FATPs are considered to be the most important factor involved in fatty acid transport and fat deposition. FATP5, a FATP subtype distributed in liver, was reported to be related to histological progression and loss of hepatic fat in Non-alcoholic fatty liver disease (NAFLD) patients (Enooku et al., 2020). Our research finds that hepatotoxicity induced by APAP can cause up-regulation of FATP5 by about 50 times, and SLE administration can reduce FATP5 to normal level. In addition, hepatotoxicity induced by APAP is found to significantly enhance the expression of DGAT2, an important enzyme for the formation of TAGs by covalent bond of DAGs and acyl-CoA. SLE administration could significantly reverse the up-regulation of DGAT2. Therefore, the effect of APAP-induced liver injury and SLE on the regulation of DAGs and TAGs is also closely related to FATP5 and DGAT2.

The protein kinase C (PKC) family, lipid-activated kinases, always plays a significant role in the regulation of diverse cellular functions (Mamidi et al., 2014). DAGs act as endogenous ligands for the PKCs in the presence of anionic phospholipids, and the accumulation of DAGs in cells can activate PKC and then

induce inflammation. Indeed, our study demonstrates that DAG (16:0/18:2/0:0) can dose-dependently reduce the survival rate of mouse primary hepatocytes. Propranolol (PNL), an inhibitor of lipins, is found to significantly reduce the levels of serum ALT and AST in the mice with liver injury apart from dependently enhancing the survival rate of hepatocytes. To clarify the mechanism of DAGs aggravating liver injury, we measured the levels of PKC α , PKC β , PKC γ , PKC δ and PKC θ in control, APAP and SLE+APAP mice. *Schisandra chinensis* can significantly reverse the upregulation of PKC β , PKC γ , PKC δ and PKC θ induced by APAP.

Acknowledgments

We acknowledge Huimin Guo, Yuhao Shao, Dian Kang, Tengjie Yu, Changjian Li, Haoran Huang, Yisha Du, He Wang for contribution to study design and execution.

Author Contribution List

Participated in research design: Yan Liang, G.J. Wang, Caixia Yan, Huimin Guo

Qingqing Ding

Conducted experiments: Caixia Yan, Huimin Guo, Yuhao Shao, Dian Kang, Tengjie

Yu, Changjian Li, Haoran Huang, Yisha Du, H. Wang

Contributed new reagents or analytic tools: Lin Xie, Huimin Guo, Caixia Yan

Performed data analysis: Caixia Yan, Yan Liang

Wrote or contributed to the writing of the manuscript: Yan Liang, G.J. Wang,

Qingqing Ding, Kangrui Hu, Caixia Yan, Huimin Guo

References

Albert D, Pergola C, Koeberle A, Dodt G, Steinhilber D, and Werz O (2008) The role of diacylglyceride generation by phospholipase D and phosphatidic acid phosphatase in the activation of 5-lipoxygenase in polymorphonuclear leukocytes. *J Leukoc Biol***83**:1019-1027.

Athuraliya TN and Jones AL (2009) Prolonged N-acetylcysteine therapy in late acetaminophen poisoning associated with acute liver failure--a need to be more cautious? *Crit Care***13**:144.

Bernal W, Lee WM, Wendon J, Larsen FS, and Williams R (2015) Acute liver failure: A curable disease by 2024? *J Hepatol***62**:S112-S120.

Bhushan B and Apte U (2019) Liver Regeneration after Acetaminophen Hepatotoxicity. *The American Journal of Pathology***189**:719-729.

Brohee L, Demine S, Willems J, Arnould T, Colige AC, and Deroanne CF (2015) Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. *Oncotarget***6**:11264-11280.

Cao B, Li M, Zha W, Zhao Q, Gu R, Liu L, Shi J, Zhou J, Zhou F, Wu X, Wu Z, Wang G, and Aa J (2013) Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells. *Metabolomics***9**:960-973.

Chen C, Krausz KW, Shah YM, Idle JR, and Gonzalez FJ (2009) Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. *Chem Res Toxicol***22**:699-707.

Chen C, Shah YM, Morimura K, Krausz KW, Miyazaki M, Richardson TA, Morgan ET, Ntambi JM, Idle JR, and Gonzalez FJ (2008) Metabolomics reveals that hepatic stearyl-CoA desaturase 1 downregulation exacerbates inflammation and

acute colitis. *Cell Metab***7**:135-147.

Chen H, Shen J, Li H, Zheng X, Kang D, Xu Y, Chen C, Guo H, Xie L, Wang G, and Liang Y (2020) Ginsenoside Rb1 exerts neuroprotective effects through regulation of *Lactobacillus helveticus* abundance and GABAA receptor expression. *J Ginseng Res***44**:86-95.

Chun JN, Cho M, So I, and Jeon JH (2014) The protective effects of *Schisandra chinensis* fruit extract and its lignans against cardiovascular disease: a review of the molecular mechanisms. *Fitoterapia***97**:224-233.

Diaz P, Harris J, Rosario FJ, Powell TL, and Jansson T (2015) Increased placental fatty acid transporter 6 and binding protein 3 expression and fetal liver lipid accumulation in a mouse model of obesity in pregnancy. *Am J Physiol Regul Integr Comp Physiol***309**:R1569-1577.

Donkor J, Sariahmetoglu M, Dewald J, Brindley DN, and Reue K (2007) Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. *The Journal of biological chemistry***282**:3450-3457.

Eastmond PJ, Quettier AL, Kroon JT, Craddock C, Adams N, and Slabas AR (2010) Phosphatidic acid phosphohydrolase 1 and 2 regulate phospholipid synthesis at the endoplasmic reticulum in *Arabidopsis*. *Plant Cell***22**:2796-2811.

Emwas AH, Luchinat C, Turano P, Tenori L, Roy R, Salek RM, Ryan D, Merzaban JS, Kaddurah-Daouk R, Zeri AC, Nagana Gowda GA, Raftery D, Wang Y, Brennan L, and Wishart DS (2015) Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. *Metabolomics***11**:872-894.

Enooku K, Tsutsumi T, Kondo M, Fujiwara N, Sasako T, Shibahara J, Kado A, Okushin K, Fujinaga H, Nakagomi R, Minami T, Sato M, Uchino K, Nakagawa H,

Kondo Y, Asaoka Y, Tateishi R, Ueki K, Ikeda H, Yoshida H, Moriya K, Yotsuyanagi H, Kadowaki T, and Koike K (2020) Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. *J Gastroenterol***55**:227-243.

Glatz JF and Luiken JJ (2017) From fat to FAT (CD36/SR-B2): Understanding the regulation of cellular fatty acid uptake. *Biochimie***136**:21-26.

Grkovich A, Johnson CA, Buczynski MW, and Dennis EA (2006) Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent. *The Journal of biological chemistry***281**:32978-32987.

Hatch GM, Smith AJ, Xu FY, Hall AM, and Bernlohr DA (2002) FATP1 channels exogenous FA into 1,2,3-triacyl-sn-glycerol and down-regulates sphingomyelin and cholesterol metabolism in growing 293 cells. *J Lipid Res***43**:1380-1389.

Hyotylainen T and Oresic M (2016) Bioanalytical techniques in nontargeted clinical lipidomics. *Bioanalysis***8**:351-364.

Jiang Y, Fan X, Wang Y, Tan H, Chen P, Zeng H, Huang M, and Bi H (2015) Hepato-protective effects of six schisandra lignans on acetaminophen-induced liver injury are partially associated with the inhibition of CYP-mediated bioactivation. *Chem Biol Interact***231**:83-89.

Kang D, Shao Y, Zhu Z, Yin X, Shen B, Chen C, Xu Y, Shen J, Li H, Li X, Xie L, Wang G, and Liang Y (2019) Systematically identifying the hepatoprotective ingredients of schisandra lignan extract from pharmacokinetic and pharmacodynamic perspectives. *Phytomedicine : international journal of phytotherapy and phytopharmacology***53**:182-192.

Klaitong P, Fa-Aroonsawat S, and Chungjatupornchai W (2017) Accelerated triacylglycerol production and altered fatty acid composition in oleaginous microalga *Neochloris oleoabundans* by overexpression of diacylglycerol acyltransferase 2. *Microbial cell factories***16**:61.

Kuo YH, Li SY, Huang RL, Wu MD, Huang HC, and Lee KH (2001) Schizandrins [corrected] B, C, D, and E, four new lignans from *Kadsura matsudai* and their antihepatitis activities. *Journal of natural products***64**:487-490.

Lan YL, Zhou JJ, Liu J, Huo XK, Wang YL, Liang JH, Zhao JC, Sun CP, Yu ZL, Fang LL, Tian XG, Feng L, Ning J, Zhang BJ, Wang C, Zhao XY, and Ma XC (2018) *Uncaria rhynchophylla* Ameliorates Parkinson's Disease by Inhibiting HSP90 Expression: Insights from Quantitative Proteomics. *Cell Physiol Biochem***47**:1453-1464.

Li L, Zhang T, Zhou L, Zhou L, Xing G, Chen Y, and Xin Y (2014) Schisandrin B attenuates acetaminophen-induced hepatic injury through heat-shock protein 27 and 70 in mice. *J Gastroenterol Hepatol***29**:640-647.

Li Y, Nie L, Jiang H, Lin J, Zhou H, Xie J, Qu Z, Qi D, and Zhang Y (2013) Metabonomics study of essential hypertension and its chinese medicine subtypes by using gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy. *Evid Based Complement Alternat Med***2013**:625906.

Lin J, Zheng S, Attie AD, Keller MP, Bernlohr DA, Blaner WS, Newberry EP, Davidson NO, and Chen A (2018) Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells. *J Lipid Res***59**:416-428.

Lin LL, Wang YH, Lai CY, Chau CL, Su GC, Yang CY, Lou SY, Chen SK, Hsu KH, Lai YL, Wu WM, Huang JL, Liao CH, and Juan HF (2012) Systems biology of meridians, acupoints, and chinese herbs in disease. *Evid Based Complement Alternat*

*Med***2012**:372670.

Liu C, Mao L, Ping Z, Jiang T, Wang C, Chen Z, Li Z, and Li J (2016) Serum Protein KNG1, APOC3, and PON1 as Potential Biomarkers for Yin-Deficiency-Heat Syndrome. *Evid Based Complement Alternat Med***2016**:5176731.

Liu H, Zhang J, Li X, Qi Y, Peng Y, Zhang B, and Xiao P (2012) Chemical analysis of twelve lignans in the fruit of *Schisandra sphenanthera* by HPLC-PAD-MS. *Phytomedicine : international journal of phytotherapy and phytopharmacology***19**:1234-1241.

Liu MY, Tang D, Shi Y, Ma L, Li Y, Zhang Q, and Ruan J (2019) Short-term inhibition of glutamine synthetase leads to reprogramming of amino acid and lipid metabolism in roots and leaves of tea plant (*Camellia sinensis* L.). *BMC Plant Biol***19**:425.

Liu X, Shi Y, Hu Y, Luo K, Guo Y, Meng W, Deng Y, and Dai R (2018) *Bupleurum marginatum* Wall.ex DC in Liver Fibrosis: Pharmacological Evaluation, Differential Proteomics, and Network Pharmacology. *Front Pharmacol***9**:524.

Mamidi N, Panda S, Borah R, and Manna D (2014) Synthesis and protein kinase C (PKC)-C1 domain binding properties of diacyltetrol based anionic lipids. *Mol Biosyst***10**:3002-3013.

Ohyama K, Baba M, Tamai M, Aibara N, Ichinose K, Kishikawa N, Kawakami A, and Kuroda N (2015) Proteomic profiling of antigens in circulating immune complexes associated with each of seven autoimmune diseases. *Clin Biochem***48**:181-185.

Panossian A and Wikman G (2008) Pharmacology of *Schisandra chinensis* Bail.: an overview of Russian research and uses in medicine. *J Ethnopharmacol***118**:183-212.

Reue K and Brindley DN (2008) Thematic Review Series: Glycerolipids. Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism. *J Lipid Res***49**:2493-2503.

Selevsek N, Chang CY, Gillet LC, Navarro P, Bernhardt OM, Reiter L, Cheng LY, Vitek O, and Aebersold R (2015) Reproducible and consistent quantification of the *Saccharomyces cerevisiae* proteome by SWATH-mass spectrometry. *Mol Cell Proteomics***14**:739-749.

Shao Y, Yin X, Kang D, Shen B, Zhu Z, Li X, Li H, Xie L, Wang G, and Liang Y (2017) An integrated strategy for the quantitative analysis of endogenous proteins: A case of gender-dependent expression of P450 enzymes in rat liver microsome. *Talanta***170**:514-522.

Shi X, Yao D, Gosnell BA, and Chen C (2012) Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity. *J Lipid Res***53**:2318-2330.

Shimizu N, Maruyama T, Yoshikawa N, Matsumiya R, Ma Y, Ito N, Tasaka Y, Kuribara-Souta A, Miyata K, Oike Y, Berger S, Schutz G, Takeda S, and Tanaka H (2015) A muscle-liver-fat signalling axis is essential for central control of adaptive adipose remodelling. *Nature communications***6**:6693.

Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, and Chinnaiyan AM (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature***457**:910-914.

Suzuki Y, Kido J, Matsumoto S, Shimizu K, and Nakamura K (2019)

Associations among amino acid, lipid, and glucose metabolic profiles in childhood obesity. *BMC Pediatr***19**:273.

Titz B, Gadaleta RM, Lo Sasso G, Elamin A, Ekroos K, Ivanov NV, Peitsch MC, and Hoeng J (2018) Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification. *International journal of molecular sciences***19**.

Wen L, Liu YF, Jiang C, Zeng SQ, Su Y, Wu WJ, Liu XY, Wang J, Liu Y, Su C, Li BX, and Feng QS (2018) Comparative Proteomic Profiling and Biomarker Identification of Traditional Chinese Medicine-Based HIV/AIDS Syndromes. *Sci Rep***8**:4187.

Xu H, Diolintzi A, and Storch J (2019a) Fatty acid-binding proteins: functional understanding and diagnostic implications. *Curr Opin Clin Nutr Metab Care***22**:407-412.

Xu S, Chen Y, Ma Y, Liu T, Zhao M, Wang Z, and Zhao L (2019b) Lipidomic Profiling Reveals Disruption of Lipid Metabolism in Valproic Acid-Induced Hepatotoxicity. *Front Pharmacol***10**:819.

Yan R, Yang Y, and Chen Y (2018) Pharmacokinetics of Chinese medicines: strategies and perspectives. *Chin Med***13**:24.

Yang L, Li M, Shan Y, Shen S, Bai Y, and Liu H (2016) Recent advances in lipidomics for disease research. *Journal of separation science***39**:38-50.

Zhang M, Xu L, and Yang H (2018a) Schisandra chinensis Fructus and Its Active Ingredients as Promising Resources for the Treatment of Neurological Diseases. *International journal of molecular sciences***19**.

Zhang P and Reue K (2017) Lipin proteins and glycerolipid metabolism: Roles at the ER membrane and beyond. *Biochim Biophys Acta Biomembr***1859**:1583-1595.

Zhang W, Huai Y, Miao Z, Qian A, and Wang Y (2019a) Systems Pharmacology for Investigation of the Mechanisms of Action of Traditional Chinese Medicine in Drug Discovery. *Front Pharmacol***10**:743.

Zhang Y, Lv X, Qu J, Zhang X, Zhang M, Gao H, Zhang Q, Liu R, Xu H, Li Q, and Bi K (2019b) A systematic strategy for screening therapeutic constituents of *Schisandra chinensis* (Turcz.) Baill infiltrated blood–brain barrier oriented in lesions using ethanol and water extracts: a novel perspective for exploring chemical material basis of herb medicines. *Acta Pharmaceutica Sinica B*.

Zhang Y, Wang Y, Li S, Zhang X, Li W, Luo S, Sun Z, and Nie R (2018b) ITRAQ-based quantitative proteomic analysis of processed *Euphorbia lathyris* L. for reducing the intestinal toxicity. *Proteome Sci***16**:8.

Footnotes

This study was supported by the Nature Science Foundation of Jiangsu Province [Grant BK20171395]; the National Nature Science Foundation of China [Grant 81530098]; and "Double First-Class" University project[Grant CPU2018GF01]. None of the authors have any financial conflicts of interest.

Figure Captions

Figure 1 Metabolomic investigation of APAP-induced hepatotoxicity and hepatoprotective function of SLE. (A) The score plots of the three groups and their OPLS-DA models for liver data (PC1, $R^2X=0.657$, $R^2Y=0.438$, $Q^2=0.424$; PC2, $R^2X=0.115$, $R^2Y=0.475$, $Q^2=0.813$; All 5 PCs). (B) Heatmap visualizing the intensities of differential metabolites in the liver samples (n=7). (C) Pathway impact of metabolites pathways.

Figure 2 Proteomics screening of differential proteins in control, APAP and SLE+APAP mice liver. (A) PCA analysis of control, APAP and SLE+APAP mice liver proteome. (C: control group; A: APAP induced liver injury group; SA: SLE+APAP group). (B) Volcano Plot of differential abundance proteins and Number of up-regulated and down-regulated proteins in Control vs APAP treated mice. (C) Volcano Plot of differential abundance proteins and Number of up-regulated and down-regulated proteins in SLE+APAP vs APAP treated mice. (D) Venn diagram of differential abundance proteins identified in three experimental groups.

Figure 3 Functional analysis of differential proteins in liver of control, APAP and SLE+APAP mice. (A) Bioinformatics analysis of 72 identified differential proteins. (B) Class of enriched KEGG Pathway. (C) Protein-Protein Interaction Graph (Circle nodes refer to genes/proteins. The boxes refer to KEGG pathways or biological processes that colored with gradient colors from yellow (smaller P-value) to blue (larger P-value). Genes/proteins are colored in red (up-regulation) and green (down-regulation).


Figure 4 Lipidomic investigation of APAP-induced hepatotoxicity and hepatoprotective function of SLE. (A) Counts of lipids that identified and percentage of different lipid species. (B) PCA analysis of lipidomics of control, APAP and SLE+APAP mice. (C) Heatmap of DGs in control, APAP and SLE+APAP mice. (D) Heatmap of TGs in control, APAP and SLE+APAP mice.

Figure 5 Mechanism of APAP-induced hepatotoxicity and SLE on the regulation of DAGs and TAGs. (A) The relative mRNA level of lipin1 in the liver (n=6). (B) Immunoblottings for lipin1 (n=3). (C) The protein levels of lipin1 (n=3) in the liver. (D) The relative mRNA level of lipin2 in the liver (n=6). (E) Immunoblottings for lipin2 (n=3). (F) The protein levels of lipin2 (n=3) in the

liver. The relative mRNA levels of (G) CD36 (H) L-FABP (I) FATP5 (J) ACC1 (K) FASN (L) DGAT2 (n=6). The results were shown with Mean \pm S.D. and * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$ were considered statistically significant. (Note: Due to the limitation of lane number, immunoblottings strips came from two pieces of gel. All the samples derived from the same experiment and that gels/bots were processed in parallel.)

Figure 6 Effect of DAGs on liver injury. (A) The influence of PNL on the foldchange of DAGs in the liver of mice with APAP induced hepatotoxicity (n=6). (B) The influence of PNL on the foldchange of DAGs in the liver of normal mice (n=6). Serum levels of (C) ALT and (D) AST were measured using kits according to manufacturer's instruction (n=6). The influence of DAG (E), DGAT2i (F) and PNL (G) on the survival rate of mouse primary hepatocytes (n=6). (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ and^{###} $P < 0.001$).

Figure 7 The mechanism of DAGs aggravating liver injury.(A) The relative mRNA level of PKC α . (B) The relative mRNA level of PKC β . (C) The relative mRNA level of PKC γ . (D) The relative mRNA level of PKC δ . (E) The relative mRNA level of PKC θ . (* $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$).







Figure 2


















Figure 4






Figure 6




Figure 7